European Psychiatry

Food for thought: understanding and treating eating disorders
pp. 1-1(1)
Author: Vandereycken W.

Post genomic psychiatry: the effect of the human genome project on clinical practice
pp. 1-1(1)
Author: McGuffin P.

A randomised Methadone-controlled heroin trial in opiod-addicts
pp. 1-1(1)
Author: van den Brink W.

Two new methods of rapid detoxification in opioid dependence: what does general anaesthesia really add to the effect?
pp. 1-1(1)
Author: de Jong C.A.J.

Sertraline alcoholics with major depression: a controlled trial
pp. 1-1(1)
Author: Gual A.

Combining acamprosate and naltrexone in the treatment of alcoholism, results from a randomized placebo controlled trial
pp. 2-2(1)
Authors: Kiefer F.; Wiedemann K.

Galanthamine - a cholinergic patch to treat alcoholics? Results of a RCT
pp. 2-2(1)
Authors: Mann K.; Scherle T.; Croissant B.; Nakovics H.

Patient treatment concordance in schizophrenia
pp. 2-2(1)
Author: Bingefors C.

Old versus new antipsychotic drugs in relation to treatment concordance
pp. 2-2(1)
Author: Wolfgang Fleischhacker W.

Compliance training programs
pp. 2-2(1)
Author: Wieselgren I.-M.

260 therapeutic drug monitorings (TDM) in relation to compliance and co-medication in psychiatric treatment
pp. 3-3(1)
Author: Bengtsson F.

The importance of drug metabolic pheno- and genotype in psychiatric co-medication issues
pp. 3-3(1)
Author: Baumann P.

Treatment-resistant depression
pp. 3-3(1)
Author: Trimble M.

Pharmacological approaches to resistant depression
pp. 3-4(2)
Author: Cowen P.J.

An overview of the antidepressant properties of transcranial magnetic stimulation
pp. 4-4(1)
Authors: Schlaepfer T.E.; Kosel M.; Frick-Schroter C.; Fisch H.-U.

Vagus nerve stimulation: a potential new treatment for treatment resistant depression?
pp. 4-4(1)
Authors: Zobel A.; Wellmer J.; Freymann N.; Maier W.

The German Network Research on Schizophrenia
pp. 4-4(1)
Authors: Gaebel W.; Wolwer W.

The Swedish HUBIN Project on Schizophrenia
pp. 4-5(2)
Authors: Sedvall O.; Adolfsson R.; Agartz I.; Arnborg S.; Ekholm B.; Hall H.; Jonsson E.; McNeil T.F.; Okugawa G.; Osby U.; Owen M.J.; Terenius L.

The Italian Network for Research on Deficit Schizophrenia
pp. 5-5(1)
Authors: Galderisi S.; Cassano G.B.; Invernizzi G.; Rossi A.; del Zompo M.; Maj M.

European First Episode Schizophrenia Trial (EUFEST)
pp. 5-5(1)
Authors: Kahn R.S.; For the EUFEST Study Group

Loss of control and depression
pp. 5-5(1)
Author: Moller H.-J.

The consequences of loss of control in animal models
pp. 5-6(2)
Author: Henn F.A.

Helplessness and stress related conditions in societies and populations of transition
pp. 6-6(1)
Author: Rutz W.

Loss of control and cardiovascular morbidity
pp. 6-6(1)
Author: Kopp M.

Depression and cardiovascular morbidity
pp. 6-6(1)
Author: Deuschle M.

Feasibility and usefulness of routine outcome assessment: the South-Verona Outcome Project
pp. 6-6(1)
Authors: Ruggeri M.; Lasalvia A.; Dall'Agnola R.; Tansella M.

A comparison of needs assessed by staff and by an epidemiologically representative sample of patients with psychosis
pp. 6-6(1)
Authors: Thornicroft G.; Slade M.; Phelan M.

Issues in the routine measurement of quality of life outcome
pp. 6-7(2)
Author: Huxley P.

Impact of regular outcome assessment on treatment - the MECCA Study
pp. 7-7(1)
Authors: Priebe S.; Bullenkamp J.; McCabe R.; Hansson L.; Roessler W.; Torres-Gonzalez F.; Wiersna D.

Estimating treatment effects from trials and observational studies
pp. 7-7(1)
Author: Dunn G.

PET and SPECT in psychiatry
pp. 7-7(1)
Author: Catafau A.

PET studies of depression
pp. 7-7(1)
Author: Grasby P.

Dopamine synthesis rate in prefrontal cortex in schizophrenia by use of PET
pp. 7-7(1)
Authors: Lindstrom L.; Gefvert O.; Lundberg T.; Lagstrom B.

PET and antipsychotic drugs - background
pp. 7-8(2)
Authors: Nordstrom A.-L.; Talvik M.; Halldin C.; Farde L.

PET and antipsychotic drugs - future
pp. 8-8(1)
Authors: Tedroff J.; Carlsson A.

Developmental pathogenesis of personality disorder
pp. 8-8(1)
Author: Livesley J.

Personality - different genes or differences in gene activation?
pp. 8-8(1)
Authors: Hallman J.; Garpenstrand H.; Damberg M.; Oreland L.

Genetics and suicidal behaviour
pp. 8-9(2)
Authors: Åsberg M.; Rylander G.

Treatment outcome of personality disorders
pp. 9-9(1)
Author: Tyrer P.

Anatomy of substance P and NK1 receptors in the brain
pp. 9-9(1)
Author: Hokfelt T.

Pharmacology - a historical overview
pp. 9-9(1)
Author: Brodin E.

Diminished anxiety - and depression-related behaviors in substance P-deficient mice
pp. 9-9(1)
Authors: Bilkei-Gorzo A.; Radz I.; Zimmer A.

Substance P (NK1) receptors in mood disorders and schizophrenia
pp. 10-10(1)
Authors: Burnet P.W.J.; Harrison P.

Clinical update: substance P antagonists in patients with major depression
pp. 10-10(1)
Author: Kramer M.S.

NK-1 receptor antagonists: a review of preclinical and clinical data
pp. 10-10(1)
Authors: Chappell P.; Bachinsky M.; Seymour P.; Siuciak J.; Tingley D.; Schmidt C.; McLean S.

Obstetric complications and schizophrenia - a meta-analysis of population-based studies
pp. 10-10(1)
Authors: Cannon M.; Jones P.B.; Murray R.M.

How identical are monozygotic twins? An fMRI study on language lateralization
pp. 11-11(1)
Authors: Sommer I.E.C.; Ramsey N.F.; Graafmans D.; Mandl R.C.W.; Kahn R.S.

Obstetric complications and risk for first admission with schizophrenia: a Danish national register based study
pp. 11-11(1)
Authors: Byrne M.; Agerbo E.; Eaton W.W.; Mortensen P.B.

Fetal growth impairment - the relevance to psychiatric outcome
pp. 11-11(1)
Authors: Hultman C.M.; Cnattingius S.; Sparen P.; Lichtenstein P.

Minor physical anomalies: moving to the next phase of research
pp. 11-11(1)
Authors: Kelly B.D.; McTigue O.; Kinsella A.; Clarke M.; O'Callaghan E.; Larkin C.; Lane A.

A half-century of neurotransmitter research: impact on neurology and psychiatry
pp. 12-12(1)
Author: Carlsson A.

Welcome and opening remarks
pp. 12-12(1)
Author: Murray R.M.

Neuroplasticity
pp. 12-12(1)
Author: Spitzer M.

Acute psychosis in clinical setting
pp. 12-12(1)
Author: Young A.

Acute agitation: new treatments
pp. 12-12(1)
Author: Wright P.

Compliance, cognition and psychosis: first episode
pp. 12-12(1)
Author: Keefe R.

Acute treatment in Eastern Europe
pp. 12-12(1)
Author: Sartorius N.

Quality of life and health outcomes: what really matters
pp. 12-12(1)
Author: Knapp M.

Chairman's address: Novel treatments - a promise fulfilled?
pp. 12-12(1)
Author: Murray R.M.

Exploring cognition and frontal lobe disorders
pp. 12-12(1)
Author: van den Bosch R.J.

Taking the patient's view
pp. 12-12(1)
Author: Berntsson A.

Gene-environment interplay in relation to emotional and behavioural disturbance
pp. 13-13(1)
Author: Rutter M.

Definitions and boundaries of forensic psychiatry
pp. 13-13(1)
Author: Carpel L.

Forensic psychiatry is an integral part of general psychiatry
pp. 13-13(1)
Author: Gordon H.

Forensic psychiatry as a subspecialty of psychiatry
pp. 13-13(1)
Author: Silfen P.

The German approach to the subspeciality ''Forensic Psychiatry''
pp. 13-13(1)
Author: Sass H.

Training and education in forensic psychiatry - examining the Israeli model
pp. 13-13(1)
Authors: Margolin J.; Kalian M.

Drug metabolism of nortriptyline and consequences of metabolic drug effects
pp. 13-14(2)
Author: Nordin C.

Drug metabolism of antipsychotics and clinical consequences
pp. 14-14(1)
Authors: Baumann P.; Zullino D.; Eap C.B.

Clinical pharmacogenetic aspects of thymo- and neuroleptic drug treatment
pp. 14-14(1)
Author: Dahl M.-L.

Pharmacogenomics, pharmacogenetics and drug response
pp. 14-14(1)
Author: Lewander T.

Pharmacokinetic drug interactions of new psychotropic agents
pp. 14-14(1)
Author: Spina E.

Pharmacotherapy of female hypoactive sexual desire disorder
pp. 15-15(1)
Author: Segraves R.T.

Pharmacotherapy of sexual arousal disorders
pp. 15-15(1)
Author: Balon R.

Pharmacotherapy - orgasm disorders
pp. 15-15(1)
Author: Waldinger M.

Female hypoactive sexual desire disorder psychological treatment
pp. 15-15(1)
Author: Segraves K.B.

Pharmacotherapy of sexual dysfunction in special populations
pp. 15-16(2)
Author: Zemishlany Z.

Recent evidence on the neurodevelopmental model of schizophrenia
pp. 16-16(1)
Author: Parnas J.

Clinical and cognitive markers of the development of schizophrenia
pp. 16-16(1)
Authors: Byrne M.; Clafferty B.; Cosway R.; Grant E.; Hodges A.; Whalley H.; Lawrie S.; Cunningham-Owens D.G.; Johnstone B.C.

Structural and functional MRI in the Edinburgh high risk study
pp. 16-16(1)
Authors: Lawrie S.M.; Whalley H.; Job D.; Ebmeier K.P.; Owens D.G.C.; Johnstone E.C.

An MRI study of subjects in the prodromal phase of psychosis
pp. 16-17(2)
Authors: McGuire P.; Velakoulis D.; McGorry P.D.; Wood S.J.; Suckling J.; Philips L.J.; Yung A.R.; Bullmore E.T.; Brewer W.; Soulsby B.; Desmond P.; Pantelis C.

Disordered brain development and abnormal connectivity
pp. 17-17(1)
Author: Bullmore E.T.

Evidence based treatments for anorexia nervosa
pp. 17-17(1)
Author: Treasure J.

Evidence based treatment for bulimia nervosa
pp. 17-17(1)
Author: Wijbrand Hoek H.

Osteopenia and bone mass increase in adolescent anorexia nervosa
pp. 17-18(2)
Author: Castro Fornieles J.

Genes, environment, and eating disorders: Twin study findings
pp. 18-18(1)
Authors: Keski-Rahkonen A.; Rissanen A.; Kaprio J.; Rose R.J.

Somatic consequences of eating disorders
pp. 18-18(1)
Author: Bruna T.

Swedish support to the restructuration of psychiatry in Eastern Europe
pp. 18-18(1)
Author: Jacobsson L.

Reforming psychiatry in Eastern Europe - the WHO perspective
pp. 18-18(1)
Author: Rutz W.

Reforming psychiatric services in Bosnia Hercegovina after the war
pp. 18-19(2)
Author: Loga S.

The role of NGOs in mental health reform example - Romania
pp. 19-19(1)
Author: Tudorache B.

Analysis of obstacles for effective mental health reform in Lithuania
pp. 19-19(1)
Author: Puras D.

Subcortical vascular dementia: introduction and clinical picture/diagnosis
pp. 19-19(1)
Authors: Wallin A.; Jonsson M.; Sjogren M.

Subcortical vascular dementia: neuropathological findings
pp. 19-19(1)
Author: Munoz D.G.

Subcortical vascular dementia: cerebrospinal fluid determinations
pp. 20-20(1)
Authors: Sjogren M.; Jonsson M.; Wallin A.

Subcortical vascular dementia: pathophysiology experimental models
pp. 20-20(1)
Authors: Pantoni L.; Palumbo V.; Sarti C.

Subcortical vascular dementia. Therapeutic issues
pp. 20-20(1)
Author: Del-Ser T.

The relationship between workplace characteristics and health: a comprehensive meta-analysis
pp. 20-20(1)
Authors: Faragher B.; Cooper C.; Cass M.

Job stress-related depression - a Swedish epidemic?
pp. 21-21(1)
Authors: Nygren .; Åsberg M.; Rylander G.; Rydmark I.; Nathell L.

Burnout links to corporate culture and work group climate
pp. 21-21(1)
Authors: Lindell J.; Sandberg C.G.

Pathophysiological aspects on stress related depression and ischemic heart disease
pp. 21-22(2)
Author: Wahrborg P.

Prevention of work-related stress and ill health: options and obstacles
pp. 22-22(1)
Author: Levi L.

Dynamics of working memory in schizophrenia
pp. 22-22(1)
Authors: Ramsey N.F.; Jansma J.M.

Sensory information processing in schizophrenia: effect of atypical medications as monitored by fMRI
pp. 22-23(2)
Authors: Henn F.A.; Ende G.; Braus D.F.

Executive functions in schizophrenia
pp. 23-23(1)
Authors: Weiss E.M.; Hofer A.; Fleischhacker W.W.

FMRI and cognitive dysfunctions in schizophrenia
pp. 23-23(1)
Authors: Schlosser R.; Sauer H.

The influence of antipsychotic treatment on cortical activations in patients with schizophrenia using functional magnetic resonance imaging
pp. 23-23(1)
Authors: Sharma T.; Kuman V.

Genome-wide expression analysis reveals dyregulation of myelination-related genes in chronic schizophrenia
pp. 24-24(1)
Authors: Hakak Y.; Walker J.R.; Li C.; Wong W.H.; Davis K.L.; Buxbaum J.D.; Haroutunian V.; Fienberg A.A.

The use of the microarray-technology in schizophrenia
pp. 24-24(1)
Authors: Falkai P.; Poustka A.

Serotonin receptor gene expression in the pathology of schizophrenia
pp. 24-24(1)
Authors: Burnet P.W.J.; Eastwood S.; East S.; Crossland N.; Harrison P.

Glutamate system gene expression in schizophrenia
pp. 24-24(1)
Authors: Deakin J.R.W.; Toro C.T.; Law A.J.

Neuropeptide gene expression in psychiatric subjects
pp. 24-25(2)
Author: Hurd Y.

Oligodendroglial reduction in the prefrontal cortex in schizophrenia
pp. 25-25(1)
Authors: Uranova N.A.; Orlovskaya D.D.; Vostrikov V.M.; Rachmanova V.I.

The diagnosis and management of bipolar disorder: developments and controversies
pp. 25-25(1)
Author: Maj M.

Anxiety
pp. 25-25(1)
Author: Zohar J.

Decreasing suicide in schizophrenia: the intersept study
pp. 26-26(1)
Author: Meltzer H.Y.

Criminality of mentally ill patients in general psychiatry
pp. 26-26(1)
Author: Muller-Isberner R.

Why do some persons with schizophrenia commit crimes?
pp. 26-26(1)
Authors: Hodgins S.; Tengstrom A.

An international comparison of the profiles of forensic psychiatric patients given first and second-generation antipsychotic medications
pp. 26-26(1)
Author: Eronen M.

Preventing recidivism among schizophrenic patients with a history of crime
pp. 27-27(1)
Authors: Freese R.; Hiscoke U.; Hodgins S.

Using urine and hair to assess drug and medication use in mentally ill patients
pp. 27-27(1)
Author: Kronstrand R.

Gender differences in the prevalence of affective disorders
pp. 27-27(1)
Authors: Angst J.; Gamma A.; Ajdacic-Gross V.; Eich D.; Rossler W.

Gender differences in first episode schizophrenia
pp. 27-27(1)
Author: Hafner H.

Gender, marital status and quality of life in schizophrenia
pp. 28-28(1)
Authors: Salokangas R.K.R.; Honkonen T.; Stengard E.; Koivisto A.-M.

Gender differences in anxiety disorders
pp. 28-28(1)
Author: Wittchen H.-U.

Women and dementia
pp. 28-28(1)
Authors: Kornhuber J.; Wiltfang J.

Polysomnographic, neuroendocrine and psychometric risk factors for depression
pp. 28-28(1)
Authors: Modell S.; Ising M.; Lauer C.; Holsboer F.

Data from the biomed european consortium for affective disorders
pp. 28-29(2)
Authors: Souery D.; Mendlewicz J.

Identifying genes for bipolar disorder on chromosome 22 using a convergent functional genomics approach
pp. 29-29(1)
Author: Kelsoe J.R.

Identification of a bipolar disorder susceptibility gene locus on chromosome 12
pp. 29-29(1)
Author: Barden N.

Chromosomal abnormalities and depression
pp. 29-30(2)
Authors: Blackwood D.; Muir W.; McIntyre D.; Pickard B.

Genes and environment in ADHD
pp. 30-30(1)
Author: Thapar A.

The role of personality in influencing genetic and environmental risk factors for major depression
pp. 30-30(1)
Author: Farmer A.

Genetic influences on autism
pp. 30-30(1)
Author: Rutter M.

What do comorbidity studies with somatic disorders tell us about the etiology of schizophrenia?
pp. 30-30(1)
Author: Mors O.

Genetic and non-genetic factors in bipolar affective disorder
pp. 30-31(2)
Author: Ewald H.

Neuroanatomy, neurophysiology and neuropathology of OCD
pp. 31-31(1)
Author: Hohagen F.

Psychopharmacological treatment in severe and/or resistant OCD: Augmentation strategies
pp. 31-31(1)
Authors: Hantouche E.-G.; Allilaire J.F.

Capsulotomy, a valid treatment for extreme OCD?
pp. 31-31(1)
Authors: Andreewitch S.; Ruck C.; Flyckt K.

Deep brain stimulation in severe treatment refractory OCD
pp. 31-32(2)
Authors: Cosyns P.; Gabriels L.; Nuttin B.

Epidemiology of schizophrenia
pp. 32-32(1)
Author: Mortensen P.B.

Toxoplasma infection in schizophrenia
pp. 32-32(1)
Author: Yolken R.H.

Persistent RNA viruses and nervous system dysfunctions
pp. 32-32(1)
Author: Kristensson K.

Endogenous retroviruses and schizophrenia
pp. 32-32(1)
Authors: Karlsson H.; Schroder J.; Bachmann S.; Yolken R.H.

Depression and Borna disease virus (BDV)
pp. 32-32(1)
Authors: Bode L.; Dietrich D.E.; Ludwig H.

Amantadine treatment in neuropsychiatric disorders with BDV infection
pp. 32-33(2)
Authors: Dietrich D.E.; Bode L.; Spannhuth C.W.; Godecke-Koch T.; Ludwig H.; Emrich H.M.

Opioid genes in the actions of drugs of abuse: perspectives from human and experimental animal models
pp. 33-33(1)
Author: Hurd Y.

Gene expession in addictive disorders
pp. 33-33(1)
Author: Kreek M.J.

Microarray analysis of brain gene expression in human alcoholism
pp. 33-33(1)
Authors: Harris R.A.; Mayfield R.D.; Lewohl J.; Dodd P.

From phenotype to genes and back: a functional genomics approach to alcohol dependence
pp. 33-34(2)
Authors: Heilig M.; Sommer W.; Rimondini R.; Arlinde C.

Measurement of somatisation: a cross-cultural perspective
pp. 34-34(1)
Author: Janca A.

The epidemiology of somatization
pp. 34-34(1)
Author: Fink P.

The significance of stress in the development of fibromyalgia syndrome
pp. 34-34(1)
Author: Anderberg U.M.

The immune pathophysiology of fibromyalgia and somatoform disorders
pp. 35-35(1)
Authors: Maes M.; Janca A.; Rief W.

Hypochondria and cognitive therapy
pp. 35-35(1)
Author: Wilhelmsen I.

Epidemiology and primary-care oriented interventions for somatoform disorders
pp. 35-35(1)
Author: Rief W.

The Lundby Study - fifty years of psychiatry
pp. 35-35(1)
Authors: Nettelbladt P.; Bogren M.; Hofvendahl E.; Mattisson C.; Toraker P.; Ojesjo L.; Hagnell O.

Longitudinal study on depression in the elderly
pp. 35-35(1)
Author: Beekman A.

Depression from middle age to old age. A 32-year follow-up of women
pp. 35-36(2)
Authors: Palsson S.; Larsson L.; Tengelin E.; Waern M.; Samuelsson S.; Hallstrom T.; Dahlgren R.; Beckman N.; Levander M.; Skoog I.

A 15-year follow-up on psychotic symptoms in the non-demented elderly
pp. 36-36(1)
Authors: Ostling S.; Skoog I.

A 40-year follow-up of patients with obsessive compulsive disorder
pp. 36-36(1)
Authors: Skoog I.; Skoog G.

Longitudinal study on neurotic disorders in the elderly
pp. 36-36(1)
Author: Copeland J.

Osteoporosis in young patients with schizophrenia
pp. 36-37(2)
Authors: Fleischhacker W.W.; Malik P.; Gasser R.; Naveda R.M.; Hummer M.

Sexual side effects lead to low quality of life and non-compliance
pp. 37-37(1)
Author: Gerlach J.

Schizophrenia and diabetes mellitus
pp. 37-37(1)
Author: Melkersson K.

Risk of sudden death and putative contributing factors during antipsychotic treatment
pp. 37-37(1)
Author: Reilly J.

The epidemiological basis for rehabilitation in schizophrenia
pp. 37-37(1)
Author: Munk-Jorgensen P.

Rehabilitation with focus on cognitive training
pp. 37-38(2)
Author: Lundin L.

Work rehabilitation
pp. 38-38(1)
Author: Mueser K.T.

Interventions for tomorrow
pp. 38-38(1)
Author: Wieselgren I.-M.

The neurobiology of dopamine signaling
pp. 38-38(1)
Author: Greengard P.

First episode schizophrenia: a targeted treatment approach
pp. 38-38(1)
Author: Kopala L.

Chronic symptoms of schizophrenia: improving the outlook
pp. 38-39(2)
Author: van Os J.

Long-term treatment benefits: a lesson from the past
pp. 39-39(1)
Author: David A.

Treatment delivery: a hope for the future
pp. 39-39(1)
Author: Eerdekens M.

Exploring the pharmacology of enantiomeric drugs
pp. 39-39(1)
Author: Arnt J.

Escitalopram - progression in antidepressant therapy
pp. 39-39(1)
Author: Montgomery S.

Increasing the efficacy of antidepressant therapy without compromising the tolerability
pp. 39-39(1)
Author: Wade A.

Escitalopram - in the treatment of mood and anxiety disorders
pp. 40-40(1)
Author: Baldwin D.

Job-stress, exhaustion and depression
pp. 40-40(1)
Authors: Åsberg M.

Neuroprotective effector mechanisms of estrogens
pp. 40-40(1)
Authors: Vedder H.; Krieg J.-C.

Estrogen effects in schizophrenia - brief update and potential therapeutic implications
pp. 40-40(1)
Author: Riecher-Rossler A.

Hypoestrogenism in schizophrenic women: implications for research
pp. 41-41(1)
Author: Bergemann N.

Estrogen therapy in women with depression
pp. 41-41(1)
Author: Bitzer J.

Cerebrospinal fluid estradiol and -amyloid levels in female patients with Alzheimer's disease
pp. 41-41(1)
Authors: Schonknecht P.; Pantel J.; Klinga C.; Jensen M.; Hartmann T.; Beyreuther K.; Schroder J.

Psychosis after childbirth
pp. 41-42(2)
Author: Wieck A.

Hormones and mental disorders - focus on estrogen-serotonin interactions
pp. 42-42(1)
Author: Fink G.

Estrogen - a possible role in the treatment of schizophrenia?
pp. 42-42(1)
Author: Kulkarni J.

Future perspectives of gender hormones in neuroprotection
pp. 42-42(1)
Authors: Ehrenreich H.; Heyer A.; Siren A.-L.

Gender differences in the genetics of anxiety disorders
pp. 42-42(1)
Author: Deckert J.

Treating psychiatric symptom with TMS
pp. 43-43(1)
Authors: Ebmeier K.P.; McIntosh A.; Semple D.; Owens D.C.; Johnstone E.C.

Magnetic seizure induction for the treatment of major depression
pp. 43-43(1)
Authors: Schlaepfer T.E.; Lisanby H.S.; Fisch H.-U.; Sackeim H.A.

Transcranial magnetic stimulation as a therapeutic tool in psychiatry: what do we know about the neurobiological mechanisms?
pp. 43-43(1)
Authors: Keck M.E.; Welt T.; Muller M.B.; Post A.; Sillaber I.; Holsboer F.

Slow rTMS in major depression and schizophrenia. Review of studies and implications for future research
pp. 43-44(2)
Authors: Klein E.; Kaplan B.; Chystiakov A.V.

Transcranial magnetic stimulation and depression
pp. 44-44(1)
Author: Bolwig T.G.

Transcranial magnetic stimulation as a tool for assessment and modulation of cortical excitability in patients with major depression
pp. 44-44(1)
Authors: Chistyakov A.V.; Kaplan B.; Hafner H.; Koren D.; Feinsod M.; Klein E.

Neuromuscular abnormalities in psychosis; implications for nosology, neurodevelopment and neurotransmitter abnormalities
pp. 44-44(1)
Author: Meltzer H.Y.

Muscle histopathology in schizophrenia
pp. 45-45(1)
Authors: Borg K.; Flyckt L.; Edman G.; Ansved T.; Bjerkenstedt L.; Wiesel F.-A.

Aberrant fingertapping and electromyographical abnormalities in patients with schizophrenia
pp. 45-45(1)
Authors: Flyckt L.; Borg K.; Borg J.; Sydow O.; Edman G.; Bjerkenstedt L.; Wiesel F.-A.

EMG responses to transcranial magnetic stimulation of the motor cortex in schizophrenia
pp. 45-45(1)
Authors: Puri B.K.; Davey N.

The iceberg of obsessive-compulsive syndromes
pp. 45-45(1)
Authors: Angst J.; Gamma A.; Ajdacic-Gross V.; Eich D.; Rossler W.

The art of screening OCD in psychiatry and primary care
pp. 46-46(1)
Author: Hantouche E.-G.

Prevalence of OCD in resistant and chronic depression
pp. 46-46(1)
Author: Olie J.-P.

Screening hidden juvenile OCD
pp. 46-46(1)
Authors: Kochman F.; Hantouche E.-G.; Akiskal H.

Phenomenology and treatment of complex OCD: at the interface of bipolarity and psychosis
pp. 46-47(2)
Author: Akiskal H.S.

Research collaboration in a post-disaster setting: experience from Nicaragua
pp. 47-47(1)
Authors: Kullgren G.; Caldera T.; Palma L.

Developing research competency - examples from Southeast Asia
pp. 47-47(1)
Author: Hauff E.

The Butajira Study - a comprehensive Ethiopian study on mental disorders
pp. 47-47(1)
Authors: Alem A.; Shibre T.; Kebede D.; Kullgren G.; Jacobsson L.

Title still to come
pp. 47-47(1)
Author: Levar I.

Ethics of research collaboration with developing countries
pp. 47-47(1)
Author: Jacobsson L.

Possibilities and limitations of DTI: a methodological introduction
pp. 48-48(1)
Author: Formisano E.

DTI in neuropsychiatric disorders
pp. 48-48(1)
Author: Lovblad K.O.

Abnormal brain white matter in schizophrenia: a diffusion tensor study
pp. 48-48(1)
Authors: Agartz I.; Andersson J.; Skare S.

DTI in hallucinating schizophrenic patients
pp. 48-48(1)
Author: Hubl D.

Microstructure of temporo-parietal white matter as a basis for reading ability: evidence from DTI
pp. 48-48(1)
Author: Klingberg T.

Treatment and management of the somatizing patients -introduction
pp. 48-48(1)
Author: Lundin A.

Treatment of patients with functional gastro-intestinal disorders
pp. 48-48(1)
Author: Creed F.

Treatment of chronic fatigue syndrome: why not?
pp. 48-48(1)
Author: Sharpe M.

Cognitive/behavioral treatment of hypochondriasis
pp. 49-49(1)
Author: Barsky A.

Cognitive-behavioral therapy for the treatment and prevention of chronic pain
pp. 49-49(1)
Author: Linton S.J.

Behavioural phenotypes
pp. 49-49(1)
Authors: Curfs L.M.G.; Tuinier S.; Verhoeven W.M.A.

Psychopathology in mentally retarded patients
pp. 49-49(1)
Authors: Verhoeven W.M.A.; Tuinier S.; Sijben A.E.S.

Dual diagnosis in trisomy-21
pp. 49-50(2)
Authors: Tuinier S.; Verhoeven W.M.A.

Neuroanatomy and psychopathology of co-morbid learning disability and schizophrenia
pp. 50-50(1)
Authors: Johnstone E.C.; Doody G.A.; Owens D.G.C.; Sanderson T.

Mice lacking CCK2 receptors display reduced anxiety in the plus-maze
pp. 50-50(1)
Authors: Vasar E.; Raud S.; Veraksits A.; Runkorg K.; Matsui T.; Bourin M.; Greengrass C.J.; Volke V.; Koks S.

Natriuretic peptides modulate the psychometric and endocrine effects of cholecystokinin tetrapeptide in man
pp. 50-50(1)
Authors: Kellner M.; Jahn H.; Naber D.; Wiedemann K.

Cholecystokinin-serotonin interactions
pp. 50-51(2)
Authors: Shlik J.; Nordin C.; Sjodin I.; Gunnarsson T.; Maron E.; Toru I.

Cholecystokinin and anxiety disorders
pp. 51-51(1)
Authors: Bradwejn J.; Koszycki D.

Cholecystokinin in cerebrospinal fluid
pp. 51-51(1)
Author: Gunnarsson T.

Pentagastrin, anxiety and personality
pp. 51-51(1)
Authors: Radu D.; Åhlin A.; Svanborg P.; Lindefors N.

Current and future treatments for dementia
pp. 51-51(1)
Authors: Winblad B.; Jelic V.

State-of-the-Art in treating alcohol problems
pp. 52-52(1)
Author: Berglund M.

The non-developmental causes of schizophrenia
pp. 52-52(1)
Author: Murray R.M.

Women as refugees
pp. 52-52(1)
Author: Anton S.

Women's mental health in late life. Experience in Bihor
pp. 52-53(2)
Authors: Tataru N.; Dicker A.

Transcultural aspects of women's mental health - a view from India and Denmark
pp. 53-53(1)
Author: Jha S.K.

Human rights abuses against women
pp. 53-53(1)
Author: Dahl S.

Migration and Islamic culture in relation to women's mental health
pp. 53-53(1)
Author: Hofecker Fallahpour M.

The concept of positive symptoms from a psychopathological point of view
pp. 53-53(1)
Author: Musalek M.

Conceptualisation of negative symptoms
pp. 53-53(1)
Author: Stanghellini G.

Neurocognitive dimensions characterizing first-time psychotic patients
pp. 54-54(1)
Authors: Friis S.; Sundet K.; Rund B.R.; Vaglum P.; McGlashan T.H.

Relationship between positive, negative and cognitive symptoms
pp. 54-54(1)
Authors: Opjordsmoen S.; Friis S.; Haahr U.; Larsen T.K.; McGlashan T.; Melle I.; Rund B.R.; Simonsen E.; Vaglum P.

Mapping positive and negative symptoms using brain imaging
pp. 54-54(1)
Author: Sedvall G.

Cognitive therapy for bipolar disorders
pp. 54-55(2)
Author: Scott J.

Cognitive therapy in relapse prevention in unipolar depression
pp. 55-55(1)
Author: Paykel E.

Cognitive behaviour therapy versus pharmacotherapy in unipolar depression
pp. 55-55(1)
Author: Hautzinger M.

Interpersonal psychotherapy in depression
pp. 55-55(1)
Authors: Pull C.B.; Pull M.-C.

Perceiving the self in schizophrenia: Abnormalities in the awareness of action
pp. 55-56(2)
Author: Blakemore S.-J.

The cognitive neuropsychiatry of self perception
pp. 56-56(1)
Author: David A.

Aspects of the connection between external tasks and internal processing modalities in patients suffering from schizophrenia
pp. 56-56(1)
Author: Gallhofer B.

Misattribution of action in schizophrenic patients with Schneiderian symptoms
pp. 56-56(1)
Author: Jeannerod M.

Schizophrenia conceived as self-disorders
pp. 56-56(1)
Author: Scharfetter C.

Synaptic proteins in schizophrenia: a ''bottom-up'' approach to neural connectivity
pp. 56-56(1)
Author: Honer W.G.

Introduction and presentation of the activities of the UEMS section & board of psychiatry
pp. 56-56(1)
Author: Lindhardt A.

Recommendations on quality assurance
pp. 57-57(1)
Author: Svard K.-O.

Training in psychiatry in Europe from a perspective of the UEMS
pp. 57-57(1)
Author: Lindhardt A.

CME
pp. 57-57(1)
Author: Gomez-Beneyto M.

From emergency activities to integrated pre-emergency, emergency and post-emergency programmes
pp. 57-57(1)
Author: Rutz W.

Reconciliation requires generations - the German example
pp. 57-57(1)
Author: von Cranach M.

The impact of terror on human mind
pp. 57-57(1)
Author: Tocilj-Simonkovic G.

The mental health programme and the challenges in Bosnia-Hercegovina
pp. 57-57(1)
Authors: Lagerkvist B.; Jacobsson L.; Djeric M.; Mehic-Basara N.; Savjak N.

Community mental health and psychiatric hospitals: what strategies for reform. The Kosovar and Albanian examples
pp. 58-58(1)
Author: Urbina L.

Mental health in a divided society
pp. 58-58(1)
Author: Agani F.

International collaboration and support in the mental health programme in Macedonia
pp. 58-58(1)
Author: Wahlberg H.

Quality assurance for randomisation and survey instruments in the EDEN-Study
pp. 58-58(1)
Authors: Kallert T.W.; Schutzwohl M.; Priebe S.; Kiejna A.; Raboch J.; Nawka P.

Clinical and sociodemographic features of randomised patients in the EDEN-centres
pp. 58-59(2)
Authors: Raboch J.; Howardova A.; Hamplova J.; Bakova N.; Sekot M.; Starkova L.; Kallert T.W.

Psychopathology and social disabilities of day-hospital and inpatients during acute treatment
pp. 59-59(1)
Authors: Kiejna A.; Szajowski K.; Rymaszewska J.; Jarosz-Nowak J.; Kallert T.

Burden on relatives comparing treatment in inpatient and day-hospital settings
pp. 59-59(1)
Authors: Schutzwohl M.; Kallert T.W.; Matthes C.

Subjective evaluation criteria in the EDEN-study
pp. 59-59(1)
Authors: Priebe S.; McCabe R.; Okine A.; Wright D.; Kallert T.

Attitudes towards psychiatric genetics in the Weimar Republic
pp. 59-60(2)
Authors: Fangerau H.; Illes F.; Muller I.; Maier W.; Rietschel M.

Attitudes towards genetic research in psychiatry
pp. 60-60(1)
Author: Hauser J.

The attitudes of Turkish psychiatrists towards the genetics of mental illnesses
pp. 60-60(1)
Authors: Saylan M.; Cakir S.; Yilmaz D.; Yazici O.

Informed consent, confidentiality and ethical votes - experience from a multinational psychiatric genetic study
pp. 60-60(1)
Author: Brewster S.

The legal protection of biotechnological inventions
pp. 60-60(1)
Authors: Koenig C.; Muller E.-M.

Dimensional versus categorical models of psychosis: is there any definitive evidence?
pp. 60-61(2)
Authors: Cuesta M.J.; Peralta V.; Eraso S.; Goikoa T.; Militino A.F.; Ugarte M.D.

Evidence that three dimensions of psychosis have a distribution in the general population
pp. 61-61(1)
Authors: Stefanis N.; Hanssen M.; Smirnis N.; Avramopoulos D.; Evdokimidis I.; Verdoux H.; van Osl J.; Stefanis C.

Schizotypy and neurocognitive deficits in a non-clinical population
pp. 61-61(1)
Authors: Stefanis N.; Smyrnis N.; Avramopoulos D.; Evdokimidis I.; Stefanis C.

Antisaccade and smooth eye pursuit in a sample of 2000 young males
pp. 61-61(1)
Authors: Smyrnis N.; Stefanis N.; Evdokimidis I.; Constantinidis T.; Avramopoulos D.; Stefanis C.

Developmental instability in schizotypy and psychosis
pp. 61-62(2)
Authors: Rosa A.; Fananas L.

Abstract(s)
pp. 62-62(1)

Molecular biology of memory and its disorders
pp. 62-62(1)
Author: Kandel E.R.

Introduction to health economics:terminology and concepts - types of economic evaluations. Choice perspective. Cost components. Markov models
pp. 62-62(1)
Author: Jonssen L.

Ethical aspects - who should have the right to treatment
pp. 62-62(1)
Author: Thelander S.

Health economic evaluations in schizophrenia
pp. 62-62(1)
Author: Knapp M.

Welcome and introduction
pp. 62-62(1)
Author: Farde L.

Schizophrenia: a chronic illness seeking a long-term solution
pp. 62-62(1)
Author: Kahn R.S.

Treatments for postnatal unipolar depression: a disorder of the brain and mind
pp. 63-63(1)
Author: Cox J.L.

Group therapy for mothers with depression
pp. 63-63(1)
Authors: Hofecker Fallahpour M.; Zinkernagel Burri C.; Stockli B.; Wusten G.; Stieglitz R.-D.; Riecher-Rossler A.

Title still to come
pp. 63-63(1)
Author: Hornstein C.

Health care for mentally ill mothers - current status in Austria
pp. 64-64(1)
Authors: Klier C.M.; Schmid-Siegel B.; Kumpf-Tontsch A.; Muzik M.; Lenz G.

Early temperament and development in adolescence
pp. 64-64(1)
Authors: Pitzer M.; Laucht M.; Schmidt M.; Esser G.

Long-term outcome and prognosis of childhood-OCD
pp. 65-65(1)
Authors: Jans T.; Wewetzer C.

Bipolar disorders - relation to personality and temperament
pp. 65-65(1)
Authors: Brieger P.; Marneros A.

Anxiety and bipolar disorder
pp. 65-65(1)
Author: Perugi G.

Serotonergic disturbances in the prefrontal cortex of suicidal patients: implications for treatment and prevention
pp. 66-67(2)
Authors: van Heeringen C.; Audenaert K.

The stress-system and suicidal behaviour
pp. 67-67(1)
Authors: Traskman-Bendz L.; Pendse B.; Westrin .

UK legislation on analgesic pack sizes: impact on suicidal behaviour
pp. 67-67(1)
Authors: Hawton K.; Townsend E.

Efficacy of St. John's wort extract WS(R) 5570 in major depression - a double-blind, placebo-controlled trial
pp. 67-67(1)
Authors: Lecrubier Y.; Clerc G.; Didi R.; Kieser M.

Increased levels of D₃ dopamine receptor mRNA in blood lymphocytes of schizophrenic patients
pp. 67-68(2)
Author: Fuchs S.

Roles of the D3 receptor and brain-derived neurotrophic factor in behavioural sensitisation to psychomotor stimulants
pp. 68-68(1)
Authors: Guillin O.; Griffon N.; Diaz J.; Carroll P.; Schwartz J.C.; Sokoloff P.

Using Internet in clinical and epidemiology studies
pp. 69-69(1)
Author: Litton J.-E.

Treatment of mental disorders via the Internet
pp. 69-70(2)
Authors: Andersson G.; Carlbring P.; Strom L.; Kaldo-Sandstrom V.; Ekselius L.

What can Internet add to psychiatry?
pp. 70-70(1)
Author: Lindefors N.

Internet strategies for AEP
pp. 70-70(1)
Authors: Pull C.B.; Cloos J.M.

deCODE genetics
pp. 70-70(1)
Author: Stefanson K.

Computer-based characterization of phenotypes for genetic and pharmacogenetic studies in psychiatry
pp. 70-70(1)
Authors: Fangerau H.; Schulze T.G.; Illes F.; Ohlraun S.; Muller D.J.; Maier W.; Rietschel M.

Sleep in schizophrenia
pp. 72-72(1)
Author: Appelberg B.

Sleep and neuroendocrinology
pp. 72-72(1)
Author: Steiger A.

Sleep in anxiety disorders and stress
pp. 72-72(1)
Author: Hetta J.

Exploring antidepressant mechanisms by acute and chronic sleep effects
pp. 72-72(1)
Authors: Wilson S.J.; Argyropoulos S.; Nash J.; Hicks J.A.; Bel C.E.; Nutt D.J.

Pro
pp. 73-73(1)
Author: Wessely S.

Con
pp. 73-73(1)
Author: Maier W.

Findings from the AESOP Study
pp. 74-74(1)
Author: Jones P.B.

The development of psychosis in the Edinburgh High Risk Study
pp. 74-74(1)
Authors: Lawrie S.M.; Miller P.; Cosway R.; Whalley H.; Owens D.G.C.; Johnstone E.C.

Finding from psycho-pharmaco-epidemiological studies: implications and critical questions
pp. 74-74(1)
Authors: de Chouly de Lenclave M.-B.; Bailly D.

Empirical guidelines for the use of antidepressants in childhood depressive disorders
pp. 74-74(1)
Author: Purper-Ouakil D.

Selective serotonin re-uptake inhibitor discontinuation syndrome in children and adolescents
pp. 74-74(1)
Author: Tamam L.

New strategies in ADHD treatment
pp. 74-74(1)
Author: Bouvard M.P.

Phospholipid metabolism and schizophrenia: new clinical trials
pp. 75-76(2)
Author: Peet M.

Phospholipid metabolism and depression: new clinical trials
pp. 76-76(1)
Author: Horrobin D.F.

Hippocampal atrophy on MRI in the diagnosis of Alzheimer's disease
pp. 76-76(1)
Authors: Pelgrim-Korf E.S.C.; Scheltens P.H.

Total-tau, A_1-42 and Ubiquitin in CSF in the diagnosis of Alzheimer disease
pp. 76-76(1)
Author: Iqbal K.

CSF tau phosphorylated at threonine 231, total tau and neuronal thread protein in the diagnosis of Alzheimer's disease
pp. 77-77(1)
Authors: Hampel H.; Burger K.; Zinkowski R.; Teipel S.J.; Kohnken R.; Kerkman D.; DeBernardis J.; Kahle P.; Rapoport S.I.; Sunderland T.; Arai H.; Tapiola T.; Hoffmann-Kiefer K.; Andreasen N.; Blennow K.; Moller H.-J.; Davies P.

Tau, phospho-tau and Ab42 in cerebrospinal fluid in Alzheimer's disease
pp. 77-77(1)
Author: Blennow K.

The Chilean experience
pp. 78-78(1)
Author: Fernandez M.

The meaning of refugee trauma and recovery during the asylum-waiting process
pp. 78-78(1)
Author: DeMarinis V.

Basic symptom concept (BSC) and prodromal psychosis
pp. 79-79(1)
Author: Huber G.

The onset of schizophrenic psychosis
pp. 79-79(1)
Author: Gross G.

Conceptual problems with early stages of psychosis
pp. 79-79(1)
Author: Heinimaa M.

The prodromal symptoms of psychosis: experiences from the TOPP clinic
pp. 79-79(1)
Authors: Larsen T.K.; Arntzen B.; Helland N.; Joa I.

The programme against stigma and discrimination because of schizophrenia in Spain
pp. 80-80(1)
Author: Lopez-Ibor J.J.

Crazy? So what!? Effects of a school project on mental health and illness on students' attitudes
pp. 81-81(1)
Authors: Schulze B.; Richter-Werling M.; Matschinger H.; Angermeyer M.C.

The antistigma action programme in Slovakia: a catalyst to integration
pp. 81-81(1)
Authors: Nawka P.; Reiss C.M.; Dolobac L.

On stigma and discrimination of mentally ill - report from a WHO/EURO task force
pp. 81-81(1)
Author: Jacobsson L.

Neurobiological basics of transfer in brain
pp. 81-81(1)
Author: Meyer B.U.

Alexithymia and cerebral hemispheres
pp. 81-81(1)
Author: Joukamaa M.

Schizophrenia, autoimmune diseases and human leucocyte antigens
pp. 82-82(1)
Authors: Wright P.; Donaldson P.; Murray R.M.

Novel antipsychotics and weight gain
pp. 83-83(1)
Author: Magnusson A.

Depression and ischemic heart disease
pp. 83-83(1)
Author: Sorensen C.

What explains the increased incidence of schizophrenia in some immigrant groups to the Netherlands?
pp. 83-83(1)
Author: Selten J.-P.

Evidence that ethnic group effects on psychosis risk are confounded by experience of discrimination
pp. 83-84(2)
Authors: Janssen I.; Hanssen M.; Bak M.; Biji R.; Vollebergh W.; McKenzie K.; van Os J.

Migration and schizophrenia: a Danish population-based cohort study
pp. 84-84(1)
Authors: Cantor-Glaae E.; Bocker Pedersen C.; McNeil T.; Mortensen P.B.

The implications of behavioural genetic research for concepts and models of personality disorder
pp. 85-85(1)
Author: Livesley J.

Psychometric approaches in personality research
pp. 85-85(1)
Author: Pukrop R.

Personality disorders in ICD-10 and DSM-IV
pp. 85-85(1)
Authors: Pull C.B.; Pull M.-C.; Cloos J.M.

Psychiatric education, scientific and research activities in Yugoslavia
pp. 86-86(1)
Author: Duisin D.

Organization, ethical and legal aspects of mental health service in Yugoslavia
pp. 86-86(1)
Author: Cavic T.

Past, present and future in education in psychiatry in Romania
pp. 86-86(1)
Authors: Mihai A.; Nirestean A.

Heteromodal association cortex involvement in schizophrenia
pp. 87-87(1)
Authors: Schlaepfer T.E.; Pearlson G.

Time course of structural brain changes in schizophrenia: an update
pp. 87-87(1)
Authors: Vita A.; De Peri L.; Dieci M.

Legal mode of admission and deprivation of liberty in psychiatric care in the Nordic Countries
pp. 88-89(2)
Authors: Kjellin L.; Engberg M.; Hoyer G.; Kaltiala-Heino R.; Sigurjonsdottir M.

Measurements of perceived coercion; methodological problems
pp. 89-89(1)
Authors: Hoyer G.; Lidz C.W.; Engberg M.; Kaltiala-Heino R.; Kjellin L.; Sigurjonsdottir M.

The role of 5-HT activity in anti-psychotic treatment
pp. 89-89(1)
Authors: Bubenikova V.; Horacek J.; Platilova V.; Zavesicka L.; Bahbouh R.; Stastny F.; Palenicek T.

Brain metabolism (PET) and cognitive performance in schizophrenia
pp. 89-89(1)
Authors: Horacek J.; Kopecek M.; Spaniel F.; Zavesicka L.; Belohlavek O.; Janeba D.

Neuropsychological dysfunctions in the families of schizophrenic patients
pp. 89-89(1)
Authors: Borkowska A.; Rybakowski J.K.

Computer-assisted rehabilitation of cognitive functions in schizophrenia
pp. 89-90(2)
Authors: Rodriguez M.; Preiss M.; Mohr P.

The fetus and external agents
pp. 91-91(1)
Author: Krageloh-Mann I.

Alcohol and neurotrophic factors during pregnancy
pp. 91-91(1)
Author: Halmesmaki E.

Excitatory and inhibitory neuroreceptors: their role for the fetal alcohol syndrome
pp. 91-91(1)
Author: Liljequist S.

Alcohol and the developing organism - fetus, child and youth
pp. 92-92(1)
Author: Rydberg U.

Background factors and consequences of teenage alcohol consumption
pp. 92-92(1)
Author: Rydelius P.-A.

From specialist training to continuing medical education in Italy
pp. 92-92(1)
Authors: Perris F.; Fiorillo A.

Longitudinal study of recently resettled refugees
pp. 93-93(1)
Author: Sondergaard H.P.

Decreased level of cortisol and testosterone among massevacuated adults from Kosovo with trauma experiences and diagnosis of PTSD
pp. 94-94(1)
Author: Roth G.

The impact of torture on post-traumatic stress symptoms in massevacuated from Kosovo
pp. 94-94(1)
Author: Ekblad S.

Caregivers' encounter with somatic communication of mental ill health in a multicultural community
pp. 94-94(1)
Authors: Baamhielm S.; Ekblad S.

National Swedish introduction programme for refugees - a programme with a potential for mental health promotion
pp. 94-94(1)
Author: Lindencrona F.

Gender differences according to clinical effects of antidepressant treatment
pp. 95-95(1)
Authors: Grubbe Goetke M.; Steyerberg E.W.; Stage K.B.; Passchier J.; Kragh-Sorensen P.; Larsen J.T.

Lithium augmentation in venlafaxine non-responders: an open study
pp. 96-96(1)
Author: Bertschy G.

Antidepressant and anxiolytic effect of St. John's wort extract ZE-117
pp. 96-96(1)
Authors: Friede M.; Freudenstein J.

Efficacy and tolerability of mirtazapine in HIV-1 infected outpatients
pp. 96-96(1)
Authors: Blanch J.; de Pablo J.; Masana G.; Minarro A.; Villarroya A.; Rousaud A.; Gatell J.M.; Gasto C.

Mega-analysis of sertraline vs. fluoxetine in major depression
pp. 97-97(1)
Authors: Flament M.; Gillespie J.

Moclobemide in early poststroke depression: an open study
pp. 97-97(1)
Authors: Kasperowicz-Dabrowiecka A.; Wanat-Slupska E.; Ziolkowska-Kochan M.; Ksiazkiewicz B.; Araszkiewicz A.

Placebo-controlled efficacy comparison of escitalopram and citalopram
pp. 97-97(1)
Author: Gorman J.

Duloxetine in the treatment of depression: a double-blind placebo-controlled comparison with paroxetine
pp. 98-98(1)
Authors: Goldstein D.; Bitter I.; Lu Y.; Detke M.; Wiltse C.; Mallinckrodt C.; Demitrack M.

Olanzapine-fluoxetine combination in treatment-resistant depression
pp. 98-98(1)
Authors: Dube S.; Paul S.; Sanger T.; Van Campen L.; Corya S.; Tollefson G.

Antidepressants of the different chemical groups: clinical and neurophysiological correlations in treating depression
pp. 99-99(1)
Authors: Grigorieva E.; Dyakonov A.

Coadministration of clozapine and amisulpride in psychotic patients
pp. 99-99(1)
Authors: Ziegenbein M.; Rosenthal O.; Garlipp P.

Characteristics of acute schizophrenic patients on atypical antipsychotics
pp. 99-99(1)
Authors: Kontaxakis V.P.; Havaki-Kontaxaki B.J.; Kollias C.T.; Margariti M.M.; Stamouli S.S.; Christodoulou G.N.

Cognitive function in stable outpatients switched to ziprasidone
pp. 99-100(2)
Authors: Harvey P.D.; Meltzer H.Y.; Romano S.J.

No weight gain among demented patients after 1 year of risperidone
pp. 101-101(1)
Authors: Rabinowitz J.; Barak Y.; Paanakker L.

Ziprasidone's long-term efficacy and tolerability in schizophrenia
pp. 101-101(1)
Author: Meltzer H.Y.

Ziprasidone vs olanzapine in schizophrenia: a double-blind trial
pp. 101-102(2)
Authors: Simpson G.; Horne R.L.; Weiden P.J.; Pigott T.; Bari M.; Romano S.J.

Recent weight gain and cost of acute service use in schizophrenia
pp. 102-102(1)
Authors: Weiden P.J.; Mackell J.A.; McDonnell D.D.

Application of rispolept at heroin addiction in outpatient practice
pp. 102-102(1)
Author: Kozlov A.

Patient attitude after switch to ziprasidone from other antipsychotics
pp. 102-102(1)
Authors: Awad A.G.; Vourganti L.; Dugar A.

Aripiprazole: a dopamine-serotonin system stabilizer
pp. 103-103(1)
Authors: Kilcuchi T.; Burris K.D.; Jordan S.; McQuade R.D.

Smooth and safe transition from intramuscular to oral olanzapine
pp. 104-104(1)
Authors: Wright P.; Meehan K.; Birkett M.; David S.R.; Taylor C.C.; Morris P.; Breier A.

Risperidone and quetiapine for treatment-resistant schizophrenia
pp. 104-104(1)
Authors: Polana P.; Roveyaz E.; Colotto A.

Neurocognitive effects: aripiprazole vs olanzapine in stable psychosis
pp. 104-104(1)
Authors: Kern R.S.; Cornblatt B.; Carson W.H.; Stock E.; Saha A.R.; Ali M.W.; Ingenito G.; Green M.F.

Calming versus sedative effects of IM olanzapine in agitated patients
pp. 104-105(2)
Authors: David S.R.; Battaglia J.; Alaka K.L.; Meehan K.; Wright P.

QTc intervals: IM olanzapine treatment in acutely agitated patients
pp. 105-105(1)
Authors: Tohen M.; David S.R.; Beasley C.M.; Alaka K.

Risperidone monotherapy in secondary prophylaxis of affective and schizoaffective disorders
pp. 106-106(1)
Authors: Granenov G.M.; Kostiukova E.G.; Mosolov S.N.

Atypical antipsychotics in Parkinson's disease organic psychosis
pp. 106-106(1)
Authors: Sobow T.; Gorczowski M.

New antipsychotics in acute psychosis with spontaneous dyskinesia
pp. 106-106(1)
Authors: Marcinko D.; Filipcic I.; Jakovljevic M.

Amisulpride vs olanzapine in schizophrenia. Preliminary results on short-term analysis
pp. 107-107(1)
Authors: Fleurot O.; Martins S.; Loo H.; Peuskens J.; Rein W.

Patient and observer perspectives on venlafaxine ER efficacy in GAD
pp. 107-107(1)
Authors: Salinas E.; Pitrosky B.; Hackett D.

Do baseline gastrointestinal symptoms alter venlafaxine ER efficacy?
pp. 107-107(1)
Authors: Lydiard R.B.; Pitrosky B.; Hackett D.; White C.

Olanzapine cotherapy in prevention of recurrence in bipolar disorder
pp. 109-109(1)
Authors: Tohen M.; Chengappa K.N.R.; Suppes T.; Baker R.W.; Risser R.C.; Evans A.R.; Calaberse J.R.

Olanzapine versus divalproex sodium for bipolar mania: a 47-week study
pp. 109-109(1)
Authors: Tohen M.; Baker R.W.; Altshuler L.; Zarate C.A.; Suppes T.; Ketter T.A.; Risser R.C.; Brown E.; Luther M.F.; Gilmore J.A.; Schuh L.

Case report of 5 bipolar disorder patients (Rapid Cycling) followed for 3 years, treated with lamotrigine
pp. 109-109(1)
Author: Asghar S.A.

The bipolar spectrum disorders: implications for new drug development
pp. 109-110(2)
Author: Kogeorgos J.

Obstetric complications as risk factors for bipolar disorder
pp. 110-110(1)
Authors: Kirk Ogendahl B.; Licht R.W.; Mortensen P.B.

A diffusion tensor and metabolite spectroscopic imaging study of white matter connectivity in schizophrenia
pp. 110-110(1)
Authors: Burns J.K.; Bastin M.; Lawrie S.; Marshall I.; McGillivrary T.; Whalley H.; Job D.; Johnstone E.

Vagus nerve stimulation and fMRI in treatment-resistant depression
pp. 111-111(1)
Authors: Nahas Z.; Chae J.-H.; Lomarev M.; Denslow S.; Anderson B.; Kapp R.; Bohning D.; Geroge M.

An EEG study of visual-sensory integration in schizophrenia
pp. 112-112(1)
Authors: Peled A.; Pressman A.; Geva A.; Modai I.

Trends in BOLD response during processing emotional cues in depression
pp. 113-113(1)
Authors: Surguladze S.; Brammer M.; Phillips M.

Cerebral blood flow in bipolar disorder measured with PET: I trait effects at rest and after mood induction
pp. 113-113(1)
Authors: Kruger S.; Goldapple K.; Kennedy D.; Mayberg H.S.

Effects of VNS on regional cerebral blood flow in depressed subjects
pp. 113-114(2)
Authors: Devous M.D.; Husain M.; Harris T.S.; Rush A.J.

Auditory event-related potential and PET: functional correlations
pp. 114-114(1)
Authors: Emri M.; Glaub T.; Berecz R.; Lengyel Z.; Mikecz P.; Bartok E.; Tron L.; Degrell I.

Effectiveness and tolerance of moclobemide in treatment of mood and anxiety disorders in adolescents
pp. 115-115(1)
Author: Dabkowska M.

Psychological aspects of radiation risk perception by children after Chernobyl
pp. 116-116(1)
Authors: Kolominsky Y.; Igumnov S.; Drozdovitch V.

Lasting armed conflict in Chechnaya and mental health of children
pp. 116-116(1)
Author: Koren E.

Long-term sertraline treatment for pediatric OCD: remission rates and functional status
pp. 116-116(1)
Authors: Cook E.; Wagner K.; Chung H.; Wolkow R.; Messig M.

Psychopathology among 8 year old Danish children
pp. 116-116(1)
Authors: Petersen D.; Bilenberg N.

Risperidone in children with conduct problems and subaverage IQ
pp. 118-118(1)
Authors: Findling R.L.; Aman M.G.; De Smedt G.; Derivan A.

Risperidone in children with disruptive behaviors and subaverage IQ
pp. 118-118(1)
Authors: Findling R.L.; Fegert J.M.; De Smedt G.

Are the parents of mentally distrubed children and adolescents also disturbed?
pp. 118-118(1)
Authors: Pejovic-Milovancevic M.; Popovic-Deusic S.; Aleksic O.

Aggressive behaviour in adolescents: an open-label study with Quetiapine
pp. 118-119(2)
Authors: Bardenstein L.; Kurashov A.; Mozhginski Y.; Posochova V.

Self-reported prodromal symptoms of adolescents attending psychiatric care
pp. 119-119(1)
Authors: Suomela T.; Heinimaa M.; Ilonen T.; Korkeila J.; Huttunen J.; Ristkari T.; Salokangas R.K.R.

Does antidepressant therapy improve cognitive function in elderly depressed patients?
pp. 120-120(1)
Authors: Coffey D.; Oxman T.; Jenkyn L.; Doraiswamy M.; Burt T.; Fayyad R.; Clary C.

Dementia with delirium caused by vitamin B12 deficiency
pp. 120-120(1)
Authors: Lerner V.; Kanevsky M.

Reliable discrimination of axis II disorders in panic disorder
pp. 121-121(1)
Authors: Perez G.; Cabre M.; Gutierrez F.; Sangorrin J.; Bulbena A.; Martin-Santos R.

Psychopathological evolution in patients with bladder tumor
pp. 121-121(1)
Authors: Matos-Pires A.; Nascimento M.; Paula L.; Pires-Barreira D.; Dias J.; Cavaglia F.

Heavy cannabis users seeking treatment: prevalence of psychiatric disorders
pp. 121-121(1)
Author: Arendt M.

Experience from the first ACT-programme in Denmark. I. Baseline evaluation
pp. 122-123(2)
Authors: Aagaard J.; Achton Nielsen J.

Experience from the first ACT-programme in Denmark. II. Severe mental illness. A register diagnosis
pp. 123-123(1)
Authors: Aagaard J.; Achton Nielsen J.

Experience from the first ACT-programme in Denmark. III. The first 60 patients
pp. 123-123(1)
Authors: Aagaard J.; Nielsen C.M.; Hjorth M.; Bang B.; Nielsen J.A.

Psychiatric service by eyes of the consumers
pp. 123-124(2)
Author: Davidouski S.

Structural and procedural characteristics of psychiatric day hospitals in Eastern and Western European countries
pp. 124-124(1)
Authors: Kallert T.; Schutzwohl M.; Matthes C.; Borosova D.; Howardova A.; Okine A.; Rymaszewska J.

Prolactin secretion in response to haloperidol challenge in delusional and non-delusional depression
pp. 125-125(1)
Authors: Lykouras L.; Markianos M.; Hatzimanolis J.; Oulis P.; Christodoulou G.N.

Mitochondrial function in selected major depressive disorder patients
pp. 125-126(2)
Authors: Gardner A.; Johansson A.; Wibom R.; Nennesmo I.; von Dobeln U.; Hagenfeldt L.; Hallstrom T.

Stability of Karolinska scales of personality in chronic depression
pp. 126-126(1)
Authors: Gardner A.; Hallstrom T.

HMPAO-SPECT with computerized brain atlas (CBA) in chronic depression
pp. 126-126(1)
Authors: Gardner A.; Pagani M.; Jacobsson H.; Lindberg G.; Larsson S.A.; Wagner A.; Hallstrom T.

Clinical aspects of comorbidity of ulcer disease and depressive disorder
pp. 126-126(1)
Authors: Zagromova T.; Kornetov N.; Gerlov G.

Does change in depression status predict change in hrQoL?
pp. 126-127(2)
Authors: Amir M.; McKenna S.; Martini M.; Bushnell D.; Whalley D.; Patrick D.

Somatic and psychic presentation of depression in Italian general practice: differences in subjects with comorbid chronic medical conditions
pp. 128-128(1)
Authors: Fraticelli C.; Passamonti M.; Pigni M.

Alexithymia and depression - a one-year follow-up study
pp. 128-128(1)
Authors: Saarijarvi S.P.; Salminen J.K.; Toikka T.

A canonical analysis of self-and observer-rated depression symptoms
pp. 128-128(1)
Authors: Haudiquet V.; Hackett D.

Major depression and return to work - predictive factors
pp. 128-128(1)
Authors: Salminen J.K.; Saarijarvi S.; Toikka T.; Raitasalo R.; Tikka J.

The effects of RS-86 on sleep with respect to depression and HLA-type
pp. 128-129(2)
Authors: Adena S.M.; Ising M.A.; Lauer C.; Holsboer F.; Modell S.

Therapeutic sleep deprivation in depression: total sleep deprivation versus late partial sleep deprivation, a review of the literature
pp. 129-129(1)
Authors: Schwarzler F.; Bernecker C.; Schweinsberg M.; Giedke H.

HPA axis activation in patients with few versus multiple episodes of depression
pp. 130-130(1)
Authors: Ehnvall A.; Sjogren M.; Zachrisson O.C.G.; Ågren H.

Dementia: neuroradiological imaging and neuropsychological testing are useful and necessitive extensions of clinical diagnostics
pp. 130-130(1)
Authors: Kreis M.; Damian M.; Krumm B.; Syre M.; Speck S.; Hentschel F.

Alzheimer's disease diagnostics and the treatment at the psychiatric out-patients department
pp. 130-131(2)
Authors: Ignjatovic D.; Ignjatovic M.

Intramuscular olanzapine: efficacy and safety in acutely agitated patients with dementia
pp. 131-131(1)
Authors: Karena M.; Wang H.; David S.; Wright J.R.; Jones B.; Beasley C.M.; Feldman P.; Breier A.

The DemTect(R): a very sensitive screening instrument for mild dementia
pp. 131-131(1)
Authors: Kalbe E.; Kessler J.; Smith R.; Bullock R.; Fischer L.; Calabrese P.

Efficacy of quetiapine in the treatment of behavioral symptoms in dementia
pp. 131-131(1)
Authors: Onor M.L.; Saina M.; De Vanna M.; Aguglia E.

Depression - suicidal ideation - bulimia nervosa
pp. 133-133(1)
Authors: Martischnig A.; Lechner A.; Steinbrenner B.; Schonauer-Cejpek M.; Steinbauer M.

Eating disorders co-morbidity in heroin addicts in MMT
pp. 133-133(1)
Authors: Campana M.; Metzger M.

Leptin and its soluble receptor across the eating disorder spectrum
pp. 133-134(2)
Authors: Martiadis V.; Monteleone P.; Iannuzzi V.; Micillo C.; Maj M.

Investigation of neuroactive steroids in anorexia and bulimia nervosa
pp. 134-134(1)
Authors: Colurcio B.; Monteleone P.; De Filippis G.; De Luca L.; Maj M.

Leptin production in bulimia nervosa
pp. 134-134(1)
Authors: Longobardi N.; Monteleone P.; Tortorella A.; Fabrazzo M.; Maj M.

Plasma levels of neurosteroids in the binge eating disorder
pp. 134-134(1)
Authors: Di Lieto A.; Monteleone P.; Colureio B.; Martiadis V.; Maj M.

Evaluating a training course for GPs in the management of depression
pp. 135-135(1)
Author: Dixon C.

Development of communicative skills and self-knowledge of students
pp. 135-136(2)
Authors: Nelubova T.; Solozhenkin V.

Psychoprophylaxis and health promotion in organic psychic disturbances
pp. 136-136(1)
Authors: Gruszczynski W.; Florkowski A.

Effects of vagus nerve stimulation on sleep in depressed patients
pp. 136-136(1)
Authors: Armitage R.; Husain M.; Hoffmann R.; Rush A.J.

Very early separation and criminality
pp. 137-137(1)
Authors: Maki P.; Hakko H.; Joukamaa M.; Isohanni M.; Veijola J.

Prevalence lifetime of substance use and other addictive behaviours in high school students
pp. 137-137(1)
Authors: Riglietta M.; Campana M.

Suicide and schizophrenia: an epidemiological study in the area of Varese, Italy
pp. 137-138(2)
Authors: Fraticelli C.; Sutera R.

12-month prevalence of panic disorder in the Swedish general population
pp. 138-138(1)
Authors: Carlbring P.; Gustafsson H.; Ekselius L.; Andersson O.

Suicide risk in relation to socioecomonic, demographic, psychiatric and familial factors
pp. 138-138(1)
Authors: Qin P.; Agerbo E.; Mortensen P.B.

Treatment of agitation and agressiveness among French elderly residents
pp. 140-140(1)
Authors: Robert P.H.; Lerger J.-M.; Rebah N.; Gerard D.A.

Predictors of alcoholism in sons of alcoholics at age 40
pp. 140-140(1)
Authors: Knop J.; Penick B.C.; Jensen P.; Gabrielli W.; Nickel E.J.; Ebdrup B.

The psychiatrist's duty to protect. How?
pp. 140-140(1)
Authors: Bukhanovsky A.O.; Bukhanovskaya O.A.; Felthous A.R.; Gleyzer R.

Involuntary placement of mentally ill in the European Union - legislation and practice
pp. 140-140(1)
Authors: Dreszing H.; Peitz M.; Salize H.J.

The comparison of forensic-psychiatric traits between female and male perpetrators of murder or attempted murder
pp. 141-141(1)
Authors: Muzinic-Masle L.; Goreta M.; Jukic V.; Koic E.

The impact of intensive case management on violent patients with psychosis
pp. 142-142(1)
Authors: Walsh E.; Leese M.; Byford S.; Gilvarry K.; Samele C.; Tatten T.; Tyrer P.; Murray R.; Fahy T.

Involuntary placement of mentally ill in the European Union - admission rates and epidemiology
pp. 142-142(1)
Authors: Salize H.J.; Peitz M.; Dreszing H.

Criminal activity and mentally disordered offenders
pp. 142-142(1)
Authors: Tosic-Golubovic S.; Miljkovic S.; Djordjevic H.; Djordjevic A.; Sibinovic V.

Social anxiety disorders
pp. 143-143(1)
Authors: Kasper S.; Loft H.; Smith J.

A meta-analysis of psychological treatments for GAD
pp. 143-143(1)
Authors: Gotestam K.G.; Ottesen I.-L.; Woldset A.W.

Association between major depressive disorder and a specific haplotype of the CRH binding protein gene
pp. 145-145(1)
Authors: Claes S.; Del-Favero J.; Souery D.; Mendlewicz J.; Adolfsson R.; Van Broeckhoven C.

Interleukin-1beta gene promoter polymorphism and risk to functional psychosis
pp. 145-145(1)
Authors: Papiol S.; Martin B.; Rosa A.; Gutierrez B.; Salgado P.; Catalan R.; Gasto C.; Fananas L.

Th1 and Th2 relationship in schizophrenia - immunological, immunogenetic and therapeutic investigations
pp. 145-145(1)
Authors: Schwarz M.J.; Riedel M.; Kroenig H.; Sokullu S.; Muller N.; Ackenheil M.

States of loss of sense in late age and their role in creation of lingering depressive responses
pp. 145-146(2)
Authors: Polichtchouk Y.; Baranskaya I.; Letnikova Z.; Kolpakov A.

Atypical symptoms in geriatric depression
pp. 147-147(1)
Authors: Cimmino C.; Balista C.; Nonis E.; Amore M.

Psychotic symptoms in geriatric depression
pp. 147-148(2)
Authors: Cimmino C.; Balista C.; Franco C.; Nonis E.; Amore M.

Onset in elderly depressive patients
pp. 148-148(1)
Authors: Cimmino C.; Balista C.; Nonis E.; Amore M.

Gender differences in geriatric depression
pp. 148-149(2)
Authors: Balista C.; Cimmino C.; Nonis E.; Amore M.

Guidelines for economic evaluation of treatments for major depression
pp. 149-149(1)
Authors: Frasch K.; Neumann N.U.

Schizophrenia treatment in Europe: country differences in the SOHO Study
pp. 150-150(1)
Authors: Haro J.M.; Edgell E.T.; Frewer P.; Novick D.; Lothgren M.

Baseline results from SOHO: a pan-European, observational study
pp. 150-151(2)
Authors: Haro J.M.; Edgell E.T.; Frewer P.; Novick D.; Lothgren M.

Hospitalisation and costs for schizophrenia relapse treatment in Germany
pp. 151-151(1)
Authors: Spannheimer A.; Reitberger U.; Clouth J.; Lothgren M.

Economic aspects of bipolar disorder in Europe
pp. 151-151(1)
Authors: Lowin A.; Knapp M.; Grant D.; Gandhi G.; Edgell E.T.

Outcomes and cost's associated with different antipsychotic treatment
pp. 151-151(1)
Authors: Lindstrom E.; Mattila J.; Olsson S.; Arthur H.; Eriksson E.; Larsbro B.; Luostannen T.; Aavik-Nilsson G.; Sjokvist M.

The GAF-Scale's variability in clinical routine work
pp. 153-153(1)
Authors: Tungstrom S.; Soderberg P.; Armelius B.-.

Sense of control, control modes and adjustment to breast cancer
pp. 153-153(1)
Authors: Roiz O.; Amir M.; Koretz M.

Tokophobia: a morbid dread of childbirth
pp. 153-153(1)
Authors: Hofberg K.; Brockington I.

Mental pathology in homeless people. American and European studies
pp. 153-153(1)
Authors: Tronchoni M.; Aparicio V.; Castro E.G.; Noriega M.

Taking care and treatment in mental health
pp. 153-154(2)
Authors: Ferrannini L.; Ciancaglini P.; Peloso P.F.

Autoradiographic localisation of 5-HT receptors in the human brain
pp. 155-155(1)
Authors: Varnas K.; Hall H.; Halldin C.; Sedvall G.

Evidence for neuroplastic activity in acute schizophrenic psychosis
pp. 155-156(2)
Authors: Rothermundt M.; Peters M.; Wiesmann M.; Hettich M.; Abel S.; Rudolf S.; Kirchner H.; Arolt V.

Anatomy and function of the Corpus Callosum
pp. 156-156(1)
Authors: von Richthofen A.-S.; Voss M.; Meyer B.-U.

Monaminergic systems in depressed patients with and without suicidal behavior
pp. 156-156(1)
Authors: Baumann B.; Bielau H.; Agelink M.W.; Krell D.; Truebner K.; Danos P.; Bogerts B.

Impaired spatial learning in schizophrenic patients
pp. 158-158(1)
Authors: Friege L.; Hoell D.; Ferstl R.; Leplow B.; Aldenhoff J.

Childhood motor impairment and persistent anxiety in adolescent boys
pp. 158-158(1)
Authors: Sigurdsson E.; van Os J.; Fombonne E.

Neurotrophins in prenatally damaged brain: implications in psychiatry
pp. 158-158(1)
Authors: Fiore M.; Iannitelli A.; Bersani G.; Korf J.; Aloe L.

Mental disorders in the patients with thyroid gland diseases
pp. 158-158(1)
Authors: Piatnitski N.; Tsirkin S.

Blunted prolactin response to fenfluramine following add-on fluvoxamine
pp. 159-159(1)
Authors: Silver H.; Inteligato N.; Peled A.; Jabarin M.; Isakov V.; Ritsner M.; Modai I.; Lupovich S.

Addiction and functional brain asymmetry
pp. 160-160(1)
Authors: Chuhrova M.; Leutin V.; Stepushina N.; Kovalevskaya G.

Changes in visual evoked potentials after magnesium in anxiety disorders
pp. 160-160(1)
Authors: Libigerova E.; Gayer D.; Kremlacek J.; Tuma I.; Chlubnova J.; Libiger J.

Stimulus processing and behavior control in schizophrenic patients
pp. 160-160(1)
Authors: Schubert M.; Fischer C.J.; Fritzer G.; Stafe N.; Lemke M.R.

Effect of astrocyte grafts on the audiogenic seizures in Wistar rats
pp. 161-161(1)
Authors: Sidorenkov A.; Ermakova I.; Lermontova N.

Usage of derivatives of D-glucosamine in emotional hypertension due to stress
pp. 161-161(1)
Author: Kanurnyy I.I.

Whole blood tryptophan predicts paroxetine/clomipramine outcome in OCD
pp. 161-161(1)
Authors: Humble M.; Bergqvist P.B.F.; Bejerot S.

Acute effect of deep brain stimulation on psychopathology in OCD
pp. 162-162(1)
Authors: Gabriels L.; Cosyns P.; Nuttin B.

Attention/executive control systems hyperactivity in OCD
pp. 162-162(1)
Authors: Volpe U.; Piegari G.; Merlotti E.; Mucci A.; Galderisi S.; Maj M.

Factors influencing treatment choice in panic disorder with agoraphobia
pp. 162-162(1)
Authors: Starcevic V.; Uhlenhuth E.H.; Kolar D.; Latas M.

Combination of benzodiazepines and SSRI in treatment of panic disorder
pp. 162-162(1)
Authors: Latas M.; Starcevic V.; Trajkovic G.; Vucinic D.

Magnetic resonance imaging as precipitating factor for the development of panic attack and possibility of pre-medication with paroxetin
pp. 163-164(2)
Authors: Ignjatovic D.; Ignjatovic M.; Durcik V.

Differential diagnostics of panic disorder and following treatment of the psychiatric policlinic
pp. 164-164(1)
Authors: Ignjatovic M.; Ignjatovic D.

Hypochondriasis or pseudo? Relationship with anxiety and its treatment
pp. 164-164(1)
Authors: Carrion O.R.; Bustamante G.; Mileo R.

Comparison of paroxetine and reboxetine in panic disorder
pp. 164-164(1)
Authors: Migliarese G.; Di Pasquale D.; Michele C.; Bertani A.; Laura B.; Giampaolo P.

Paroxetine and respiration in panic disorder: preliminary results
pp. 164-164(1)
Authors: Cucchi M.; Di Pasquale D.; Bertani A.; Caldirola D.; Bellodi L.; Perna G.

Respiratory irregularity in respiratory subtype panic
pp. 165-165(1)
Authors: Caldirola D.; Cucchi M.; Bertani A.; Migliarese G.; Biffi S.; Bellodi L.; Perna G.

A naturalistic fifteen-year follow-up study of panic disorder patients
pp. 166-166(1)
Authors: Andersch S.; Hetta J.

Psychosis proneness scales and DSM schizophrenia spectrum personality disorders
pp. 166-166(1)
Author: Laurent A.

Behavior control after induction of emotion in borderline personality disorder
pp. 166-166(1)
Authors: Fischer C.J.; Wendorff T.; Lemke M.R.

The process of mentalisation in borderline
pp. 166-167(2)
Authors: Messini E.; Papastathopoulos E.; Theodorou A.; Gasparatou O.; Angelopoulou M.; Paliokosta E.

Clinically significant subgroups of borderline personality disorder (PD)
pp. 167-167(1)
Authors: Karterud S.; Pedersen G.

A study of quality of life in outpatients with personality disorders
pp. 168-168(1)
Authors: Narud K.; Mykletun A.; Dahl A.A.

Diagnostic procedure in psychiatry: the structuralist approach
pp. 168-168(1)
Authors: Zislin J.; Kuperman V.

Contemporary history of psychiatry
pp. 168-169(2)
Author: Kringlen E.

Generating prediction rules: dependence on the mathematical model
pp. 169-169(1)
Author: Schultze-Lutter F.T.K.

Social stresses in relation to psychiatric morbidity in menopause
pp. 169-169(1)
Authors: El-Hinnawey A.; Khafagi A.; Gawad M.

The comparative clinical analysis of endogenic psychoses in health resort conditions
pp. 169-169(1)
Author: Vyetrila T.

Changes in patients' attitude due to changes in the psychiatry concept
pp. 170-170(1)
Author: Gerulaitiene D.M.

Quality of life psychotics during the aerial bombing of Yugoslavia
pp. 171-171(1)
Authors: Mandic-Gajic G.; Samardzic R.; Spiric Z.; Preradovic M.

Prader-Willi syndrome and atypical psychoses
pp. 171-171(1)
Authors: Verhoeven W.M.A.; Curfs L.M.G.; Tuinier S.

Evolution of epileptic psychosis
pp. 171-171(1)
Authors: Kazakovcev B.A.; Maxutova E.L.; Sokolova L.V.

Period of adolescence - psychiatric differentiation of symptomatology
pp. 171-171(1)
Authors: Leposavic L.; Barac Z.; Lakic A.; Barisic-Rojnic J.; Nikolic-Balkoski G.; Milovanovic S.

24 hour-HRV in relation with weight and BMI in 92 mentally healthy probands
pp. 173-173(1)
Authors: Acker J.; Kaschka W.P.; Topf G.

Behavioral activation or inhibition during emotional stress
pp. 173-173(1)
Authors: Seigel K.; Broman J.-E.; Hetta J.

P3 and negative disorders scores in patients with schizophrenia
pp. 173-173(1)
Authors: Lebedeva I.; Kaleda V.; Orlova V.; Fedorova E.

Psychopathology of schizophrenia and gating of auditory evoked potentials P50
pp. 173-173(1)
Author: Wegrzyn J.

A specialized group- treatment programme for depressive inpatients. Catamnestic results
pp. 174-174(1)
Authors: Schwarzler F.; Smoltczyk H.; Batra A.; Buchkremer G.

Life events, social support and the onset of major depressive episode
pp. 175-175(1)
Authors: Leskela U.S.; Melartin T.K.; Lestela-Mielonen P.S.; Rytsala H.J.; Sokero T.P.; Heikkinen M.E.; Isometsa E.T.

''New chronics'' - do they need psychiatry-adjacent homes?
pp. 176-176(1)
Authors: Franz M.; Meyer T.; Adenaw C.; Gallhofer B.

Predictors of health-related distress in family caregivers
pp. 176-176(1)
Authors: Franz M.; Meyer T.; Gallhofer B.

Restrictiveness of psychiatric institutions - a changing pattern
pp. 176-176(1)
Authors: Hanewald B.; Franz M.; Meyer T.; Gallhofer B.

Who says what? - Statements by schizophrenics and their psychiatrists on the current neuroleptic medication
pp. 180-180(1)
Authors: Langle G.; Koster M.; Waschulewski H.

Self-control and frontal lobe function in psychosis
pp. 180-180(1)
Authors: Jansson J.-.; Gervind B.; Warkentin S.

Cannabis use and the expression of psychosis vulnerability in daily life
pp. 180-180(1)
Authors: Verdoux H.; Gindre C.; Sorbara F.; Tournier M.; Swendsen J.

Cannabis use and dimensions of psychosis in a non-clinical population of female subjects
pp. 180-181(2)
Authors: Verdoux H.; Sorbara F.; Gindre C.; Swendsen J.; van Os J.

Lycanthropy - psychopathology and psychodynamics
pp. 181-181(1)
Authors: Garlipp P.; Godecke-Koch T.; Haltenhof H.; Dietrich D.E.

Association study and meta-analysis of a DRD3 gene Ser9Gly variant and schizophrenia
pp. 182-182(1)
Authors: Jonsson E.G.; Flyckt L.; Burgert E.; Crocq M.-A.; Forslund K.L.; Mattila-Evenden M.; Rylander G.; Åsberg M.; Nimaonkar V.L.; Edman G.; Bjerkentstedt L.; Wiesel F.-A.; Sedvall G.

Data mining in schizophrenia in the Human Brain Informatics Project
pp. 182-182(1)
Authors: Hall H.; Arnborg S.; Agartz I.; Sedvall G.

Pindolol augmentation in aggressive schizophrenic patients
pp. 182-182(1)
Authors: Modai I.; Caspi N.; Barak P.; Waisbourd A.; Zbarsky E.; Hirschmann S.; Ritsner M.

Paroxetine binding in aggressive schizophrenic patients
pp. 183-183(1)
Authors: Modai I.; Gibel A.; Rauchverger B.; Ritsner M.; Klein E.; Ben Shachar D.

Mitochondrial function in neuroleptic-free and medicated schizophrenia
pp. 183-183(1)
Authors: Gardner A.; Wibom R.; Nennesmo I.; von Dobeln U.; Beier H.; Hagenfeldt L.; Hallstrom T.

Psychiatric comorbidity in schizophrenia with obsessive compulsive disorder
pp. 184-184(1)
Authors: Poyurovsky M.; Schneidman M.; Weizman A.; Weizman R.

QLIS - a new schizophrenia-specific quality of life scale
pp. 184-185(2)
Authors: Meyer T.; Franz M.

The subjective/objective dichotomy in schizophrenia-data from Striatal Dopamine Depletion Study
pp. 185-185(1)
Authors: Awad A.G.; Voruganti L.N.P.

Cognitive dysfunctions in prepsychosis
pp. 185-185(1)
Authors: Bartok E.; Berecz R.; Glaub T.; Degrell I.

Reduced energy metabolism in schizophrenia
pp. 185-185(1)
Authors: Nilsson B.M.; Forslund A.; Olsson R.; Saldeen T.; Hambreus L.; Wiesel F.-A.

Body composition changes in patients with schizophrenia
pp. 186-186(1)
Authors: Nilsson B.M.; Forslund A.; Olsson R.; Hambreus L.; Wiesel F.-A.

Ziprasidone vs olanzapine in schizophrenia: a 6-month extension study
pp. 186-187(2)
Authors: Simpson O.; Horne R.L.; Weiden P.; Pigott T.; Bari M.; Romano S.J.

Patient knowledge about schizophrenia and treatment compliance
pp. 187-187(1)
Authors: Melcer P.; Rabe-Jablonska J.

Neurological soft signs (NSS) in schizophrenia
pp. 188-188(1)
Authors: Bersani G.; Gherardelli S.; Ramieri L.; Orlandi V.; Pucci D.; Pancheri P.

Biochemical origin of the schizophrenia and of the behavioral pathologies of schizoid type
pp. 188-189(2)
Author: Chirieleison G.

Pharmacokinetics of psychotropics
pp. 189-189(1)
Authors: Tuinier S.; Verhoeven W.M.A.; Sijben A.E.S.

Valproic acid in unstable mood disorder
pp. 189-189(1)
Authors: Tuinier S.; Verhoeven W.M.A.

Atypical antipsychotics in schizophrenia; efficacy and effect on serotonergic parameters
pp. 189-189(1)
Authors: Tuinier S.; Verhoeven W.M.A.; van der Heijden F.M.M.A.; Sijben A.E.S.

Citalopram in mentally retarded patients with depression
pp. 189-190(2)
Authors: Verhoeven W.M.A.; Tuinier S.

Psychopharmacotherapy or psychotherapy of anxiety disorders - one year results
pp. 190-191(2)
Authors: Ignjatovic D.; Ignjatovic M.

Synthesis of endogenous ethanol during treatment of alcoholic dependence
pp. 191-191(1)
Authors: Chuhrova M.; Timofeyev I.

Creatine kinase levels during treatment with atypical antipsychotic agents
pp. 191-191(1)
Authors: Reznik I.; Mester R.; Spivak B.; Kotler M.; Weizman A.; Meltzer H.Y.

Alteration of hormone status during the treatment of risperidon
pp. 191-191(1)
Authors: Kochetkov Y.; Bulanov V.; Gorobets L.; Komissarov P.

Correction of hyperprolactinemia under risperidon treatment
pp. 192-192(1)
Authors: Bulanov V.; Gorobets L.; Vasilenko L.; Granenov G.; Mosolov S.

Increased use of antidepressants beneficial for depressed individuals
pp. 192-192(1)
Authors: Henriksson S.; Isacsson G.

Cognition in elderly schizophrenic patients: risperidone vs olanzapine
pp. 192-192(1)
Authors: Harvey P.D.; Mao L.; Napolitano J.; Gharabawi G.

Plasma leptin and weight gain during clozapine treatment
pp. 193-193(1)
Authors: Fuschino A.; Monteleone P.; Pia S.L.; Bencivenga R.; Maj M.

Improvement in general life functioning with venlafaxine versus fluoxetine in outpatients with major depression
pp. 194-194(1)
Authors: Kalin N.; Nemeroff C.; Wan G.; Panish J.; Cantillon M.

Improvement in social activity level, general life and cognitive functioning with venlafaxine versus fluoxetine in inpatients with melancholic depression
pp. 194-194(1)
Authors: Evans D.; Nemeroff C.; Thase M.; Wan G.; Panish J.; Cantillon M.

Maternal recall bias in the obstetric histories of individuals with and at increased risk of schizophrenia
pp. 194-194(1)
Authors: McIntosh A.M.; Holmes S.-E.; Gleeson S.; Burns J.K.; Hodges A.; Byrne M.; Dobbie R.; Miller P.; Lawrie S.; Johnstone E.

Steroid-induced granulocytosis in neutropenic patients treated by clozapine
pp. 194-195(2)
Authors: Murray P.; Laurent A.

Gene expression profiling of human neuronal cells treated with antipsychotics in vitro
pp. 195-195(1)
Authors: von Widdern O.; Wirths O.; Boenisch H.; Bayer T.; Maier W.; Rietschel M.

Patient satisfaction as a marker of psychiatric treatment quality - the TUBB2000
pp. 196-196(1)
Authors: Langle G.; Schmidt-Hackenberg M.; Waschulewski H.

Evaluation of psychiatric day treatment
pp. 196-196(1)
Authors: Garlipp P.; Haltenhof H.; Bruggemann B.; Vossschulte H.; Stritt K.; Seidler K.-P.

Data base of quality in psychiatric outpatient treatment. DIPSY
pp. 196-197(2)
Author: Aagaard J.

Patterns of use of acute psychiatric units in Andalousia (Spain)
pp. 197-197(1)
Authors: Miguel Pena-Andreu J.; Martinez Gonzalez J.L.; Rodriguez Idigoras M.I.; Jimenez Lerida G.; Ruiz Ruiz M.; Jimenez Sarmentero M.M.

Analysis of subgroups of psychiatric admissions in Andalousia (Spain)
pp. 197-197(1)
Authors: Miguel Pena-Andreu J.; Martinez Gonzalez J.L.; Rodriguez Idigoras M.I.; Fernandez Terron M.J.; Martinez Cabrera M.D.

A model to evaluate the reliability of the GAF-scale
pp. 197-197(1)
Authors: Soderberg P.; Tungstrom S.; Armelius B.-A.

The relationship between personality and post traumatic stress disorder
pp. 198-198(1)
Author: Sohrabi F.

Mental symptoms in victims of sarin poisoning 5 years after the Tokyo subway attack
pp. 199-199(1)
Authors: Iwanami A.; Toshiyuki O.; Mamoru T.; Tadafumi K.; Tsukasa S.; Nobumasa K.

Longterm effects of traumatic experiences in refugees after World War II
pp. 199-199(1)
Authors: Fischer C.J.; Struve J.; Lemke M.R.

Prophylaxis by mexidol of the behavior disturbances after sound stress
pp. 199-199(1)
Authors: Loseva E.; Alekseeva T.; Mering T.

A psychosocial model of posttraumatic stress after childbirth
pp. 199-199(1)
Authors: Arzy-Sharabani R.; Amir M.; Hallak M.

Previous trauma, personality dimensions and psychological symptoms after a stressful event
pp. 199-200(2)
Authors: Lecic-Tosevski D.; Priebe S.; Gavrilovic J.; Dimic S.; Knezevic G.

Aerial bombing of Yugoslavia: coping styles and traumatic reactions
pp. 200-201(2)
Authors: Zeljko S.; Samardzic R.; Knezevic G.; Preradovic M.; Bjelica N.; Zujovic T.; Antonijevic J.

Chronic pain in the wives of the Croatian war veterans treated for PTSD
pp. 201-201(1)
Authors: Koic E.; Muzinic-Masle L.; Franciskovic T.; Vondracek S.; Djordjevic V.; Per-Koznjal J.; Prpic J.

Coping styles: a hopelessness and suicide risk
pp. 201-201(1)
Authors: Yang T.-T.; Ming C.

Hostility and depression in diabetic patients
pp. 201-201(1)
Authors: Krausova Z.; Dryakova M.; Honzak R.; Tichy V.

Comparative study of psychotherapy effectiveness of acute life-events depression, acute and posttraumatic stress disorders in men and women
pp. 202-202(1)
Author: Tukaev R.

Psychosocial consequences of the 1998 Landslide in Samo, Italy
pp. 202-202(1)
Authors: Malafronte R.; Catapano F.; Cozzolino P.; Magliano L.; Maj M.

PTSD and psychosis
pp. 202-202(1)
Authors: Bjelica N.; Slovakovic S.; Preradovic M.; Spine Z.; Samardzic R.

Assessment of medical consumption among suicide attempters
pp. 203-203(1)
Authors: Walter M.; Garre J.B.; Eudier F.; Martineau W.; Chavagnat J.J.; Chastang F.; Levy D.; Nabhan-Abou N.; Nguyen M.; Lemoigne L.; Chanudet C.; Cordier J.P.; Cadiet L.; Houdet D.; Dhont P.

Effects of climatic factors on suicide attempts in Northern Turkey
pp. 203-203(1)
Authors: Doganay Z.; Guz H.; Ozkan A.; Sunter T.; Altyntop L.; Kati C.; Colak E.; Guven H.; Aygun D.

Suicide attempts in Northern Turkey
pp. 204-204(1)
Authors: Doganay Z.; Guz H.; Ozkan A.; Sunter T.; Altyntop L.; Colak E.; Kati C.; Guven H.; Aygun D.

Psychiatric treatments of patients before hospitalisation after a tentamen
pp. 204-204(1)
Authors: Orha F.A.; Zullino D.F.; Baumann P.

Risk factors for suicidal ideation and attempts among psychiatric patients with major depressive disorder
pp. 204-204(1)
Authors: Sokero T.P.; Leskela U.S.; Rytsala H.J.; Lestela-Mielonen P.S.; Melartin T.K.; Isometsa E.T.

Risk factors of suicide in in-patients and recently discharged patients with affective disorders
pp. 204-204(1)
Authors: Hoyer E.H.; Licht R.W.; Mortensen P.B.

Suicide after discharge from psychiatric hospital in Oslo, Norway
pp. 205-205(1)
Authors: Walby F.A.; Ekeland H.; Mehlum L.

Time perspective in suicide attempters
pp. 206-206(1)
Author: Ripke B.

Self-aggression of soldiers and possibilities of psychoprophylaxis
pp. 206-206(1)
Authors: Florkowski A.; Gruszczynski W.

Suicide in mental health service users diagnosed with schizophrenia
pp. 206-206(1)
Authors: Hunt I.; Meehan J.; Robinson J.; Shaw J.; Appleby L.

Conversion disorders and the subtypes
pp. 206-207(2)
Authors: Guz H.; Doganay Z.; Ozkan A.; Colak E.; Tomac A.; Sarysoy G.

Conversion and somatization disorders: the dissociative symptoms and other characteristics
pp. 207-207(1)
Authors: Guz H.; Doganay Z.; Ozkan A.; Colak E.; Tomac A.; Sarysoy G.

Sexual disturbances in 4557 depressed patients: a French survey
pp. 208-208(1)
Author: Bonierbale M.

Sleep quality in schizophrenic patients taking antipsychotics
pp. 209-209(1)
Author: Schreiner A.

Sleep deprivation effects on subjective sleep clomplaints
pp. 209-209(1)
Authors: Cavaglia F.; Pires-Barreira D.; Paula L.; Matos-Pires A.; Arriaga F.

Circannual variation of sleep disturbances and psychiatric symptoms
pp. 209-209(1)
Authors: Neckelmann D.; Mykletun A.; Dahl A.A.

Sleep complaints predict coronary artery disease mortality in males: a twelve-year follow-up study of a middle-aged Swedish population
pp. 209-209(1)
Authors: Mallon L.; Hetta J.; Broman J.-E.

Cognitive evoked potentials P300 in patients with alcohol dependence F10.1
pp. 210-211(2)
Author: Sundric Z.

Perception of emotions by alcoholic patients during long-term treatment with naltrexone
pp. 211-211(1)
Authors: Ziokowski M.; Araszkiewicz A.; Rybakowski J.K.

Alcohol dependence is associated with a NMDA-receptor 2B gene variant
pp. 212-212(1)
Authors: Schumann G.; Rujescu D.; Szegedi A.; Singer P.; Wiemann S.; Wellek S.; Giegling I.; Klawe C.; Anghelescu I.; Heinz A.; Spanagel R.; Mann K.; Henn F.A.; Dahmen N.

The association between alcohol and suicide rate: results of time-series analysis
pp. 212-212(1)
Author: Razvodovsky Y.E.

Endogenous ethanol and microbe associations at patients with alcoholic dependence
pp. 213-213(1)
Authors: Perminova N.; Chuhrova M.; Timofeyev I.

Efficacy of oxcarbazepin in alcohol relapse prevention - a pilot study
pp. 213-213(1)
Authors: Croissant B.; Scherle T.; Heinz A.; Mann K.

Addiction, stigma and the movies
pp. 213-213(1)
Author: Cape G.

Population survey of drug abusers attending a Swiss detoxification unit
pp. 213-213(1)
Authors: Krenz S.L.; Zullino D.F.; Zimmermann G.; Favrad B.; Eichenberger C.; Dieckman S.; Besson J.

Topiramate in multidrug withdrawal - comparison with clonidine
pp. 213-214(2)
Authors: Krenz S.L.; Zimmermann G.; Pin M.; Kolly S.; Besson J.; Zullino D.

Heroin addiction and its social consequences in Russia
pp. 215-215(1)
Author: Tchistyakova L.

Patient or client, what substance misuse attenders want to be called, who they want to be treated with, where they want to be seen
pp. 215-215(1)
Authors: Keaney F.; Martinez-Raga J.

Does cannabinoid exposure sensitize the brain to amphetamine effects?
pp. 215-215(1)
Authors: Stridh M.; Kuhne S.; Hurd Y.; Franck J.

Cocaine mediated dopamine transmission and behavior in depressed rats
pp. 215-216(2)
Authors: Fagergren P.; Overstreet D.H.; Hurd Y.L.

Impaired dopamine-related motivation in nicotine addicts after overnight abstinence
pp. 216-216(1)
Authors: Schmidt L.G.; Budde H.; Smolka M.

Treatment of drug addicts - drop out, completion and stages of change
pp. 216-216(1)
Authors: Gunthner A.; Mann K.; Buchkremer G.; Bader T.

Drug abuse among Bosnian adolescents and its risk related behaviour
pp. 217-217(1)
Authors: Licanin I.; Music E.; Dedic A.; Paralija B.

Internet-based psychiatric assessment of tinnitus patients
pp. 217-217(1)
Authors: Kaldo-Sandstrom V.; Carlbrin P.; Strom L.; Andersson G.

Randomized controlled trial of internet-based treatment of insomnia
pp. 218-218(1)
Authors: Andersson G.; Strom L.; Pettersson R.

Combining 1-Hz and 10-Hz rTMS in the treatment of depressives
pp. 218-218(1)
Authors: Conca A.; Peschina W.; Hausmann A.; Koenig P.

Dynamics of vegetative regulation in transcranial magnetic stimulation of depressed patients
pp. 218-218(1)
Authors: Melnikova T.S.; Mosolov S.; Tsoukarzi E.; Kapiletti S.

Accessibility of drug treatment institutions for migrants in Germany
pp. 218-218(1)
Authors: Heinz A.; Krieg S.; Hunner C.; Penka S.

Schizophrenia as a systemic disorder - studies of peripheral and central biological functions
pp. 219-219(1)
Authors: Flyckt L.; Edman G.; Bjerkenstedt L.; Venizelos N.; Hagenfeldt L.; Wiesel F.-A.

Neurological signs in schizophrenia: trait markers of brain dysfunction
pp. 220-220(1)
Author: Arango C.

Speech processing cortical representation: invariance in left superior temporal sulcus and variability in Broca's area
pp. 220-220(1)
Authors: Dollfus S.; Josse G.; Joliot M.; Crivello F.; Papathanassiou D.; Mazoyer B.; Tzourio-Mazoyer N.

Genotyping Reelin in multiple affected families with schizophrenia: a suitable marker for the vulnerability to develop schizophrenia?
pp. 220-220(1)
Authors: Falkai P.; Neidt I.; Tepest R.; Muller D.; Schulze T.; Gross M.; Maier W.; Schild H.; Block H.; Rietschel M.

Introducing a new recruitment design for genetic association studies in opioid dependence
pp. 220-220(1)
Authors: Franke P.; Wendel B.; Knapp M.; Schwab S.G.; Maier W.; Wildenauer D.B.; Hoehe M.R.

In opioid dependence
pp. 220-220(1)
Author: Galderisi S.

Pharmacoeconomics of the treatment of agoraphobia with panic disorder
pp. 222-222(1)
Authors: Ignjatovic M.; Ignjatovicova D.; Hosak L.

Clinical features of major depression in offspring and history of major depression in parents: findings from a prospective community study of adolescents and young adults
pp. 222-222(1)
Authors: Lieb R.; Hofler M.; Wittchen H.-U.

Reversal of paracingulate sulcus asymmetry patterns in men with early-onset schizophrenia
pp. 222-222(1)
Authors: Le Provost J.B.; Bartres-Faz D.; Paillere-Martinot M.L.; Artiges E.; Pappata S.; Recasens C.; Perez-Gomez M.; Bernardo M.; Baeza I.; Bayle F.; Martinot J.L.

Family psychoeducation in schizophrenia and quality of life
pp. 222-223(2)
Authors: Motlova L.; Dragomirecka E.; Spaniel F.

Service and non-service costs of psychiatric patients attending a community mental health centre in Italy
pp. 223-223(1)
Authors: Percudani M.; Barbui C.; Beecham J.; Knapp M.

Depression, anxiety, aggression, impulsivity and suicidal behavior
pp. 223-223(1)
Authors: Pitchot W.; Paquay C.; Reggers J.; Ansseau M.

Brain glucose metabolism after dextromethorphan challenge in alcohol dependent males and controls
pp. 223-224(2)
Authors: Schutz C.G.; Ruther T.; Koch R.; Soyka M.; Tatsch K.

Dissociation, pain threshold and treatment of eating disorders
pp. 225-225(1)
Authors: Papezova H.; Yamamova A.; Vurmova I.; Hajkova I.; Kocova M.

The candidate gene approach in affective disorder: the European Collaborative Project on Affective Disorders
pp. 225-225(1)
Author: Souery D.

Author index
pp. 227-240(14)